Promoter Hypermethylation Correlates with the Hsulf-1 Silencing in Human Breast and Gastric Cancer
Overview
Authors
Affiliations
The HSulf-1 gene is an important factor that modulates the sulfation status of heparan sulfate proteoglycans (HSPGs) in the extracellular matrix, resulting in disturbance of HSPG-related signal transduction pathways. Recently, HSulf-1 has been reported to be down-regulated in several human cancers. In this study, we first cloned and characterized the 5' promoter region of the HSulf-1 gene (around 400 bp) that contained high basal promoter activity. We also found that this functional promoter region was hypermethylated in a number of human cancer cell lines. Furthermore, we found that hypermethylation in this promoter region correlated with the down-regulation of the HSulf-1 expression in human breast and gastric cancer cell lines and tissue samples. These results suggest that the promoter hypermethylation may be one of the mechanisms of the HSulf-1 gene silencing in human breast and gastric cancers. Finally, we demonstrated that the HSulf-1 promoter was more frequently (p<0.05) methylated in cell-free DNA extracted from serum samples of human breast and gastric cancer patients than that of healthy people (76.2%, 55.0% and 19.0%, respectively), indicating that detection of the HSulf-1 promoter methylation in serum samples may have clinical implications in early detection and diagnosis of human breast and gastric cancers.
Han M, Zhu H, Chen X, Luo X Am J Cancer Res. 2024; 14(2):897-916.
PMID: 38455409 PMC: 10915330.
Bioinformatics analysis of the genes associated with co-occurrence of heart failure and lung cancer.
Wang X, Song R, Li X, He K, Ma L, Li Y Exp Biol Med (Maywood). 2023; 248(10):843-857.
PMID: 37073135 PMC: 10484198. DOI: 10.1177/15353702231162081.
DNA Methylation: An Important Biomarker and Therapeutic Target for Gastric Cancer.
Zeng Y, Rong H, Xu J, Cao R, Li S, Gao Y Front Genet. 2022; 13:823905.
PMID: 35309131 PMC: 8931997. DOI: 10.3389/fgene.2022.823905.
Heparan Sulfate Glycosaminoglycans: (Un)Expected Allies in Cancer Clinical Management.
Faria-Ramos I, Pocas J, Marques C, Santos-Antunes J, Macedo G, Reis C Biomolecules. 2021; 11(2).
PMID: 33494442 PMC: 7911160. DOI: 10.3390/biom11020136.
Chen F, Zhang Z, Yu Y, Liu Q, Pu F Int J Oncol. 2020; 57(1):223-236.
PMID: 32377705 PMC: 7252455. DOI: 10.3892/ijo.2020.5057.